An advisory panel to the FDA has recommended Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.


The US Food and Drug Administration (FDA) has rejected Alkermes’ New Drug Application for ALKS 5461, a proposed adjunctive treatment for major depressive disorder, citing the need for additional clinical data exhibiting its effectiveness.

When a teen is diagnosed with depression, it's normal for parents to feel overwhelmed and to search for information about which treatment options are best, doctors write in a new patient resource published January 28 online in JAMA Pediatrics.

First-time mothers who give birth by unplanned cesarean section are 15% more likely to experience postnatal depression, according to a study in the Journal of Health Economics.

Children and adolescents who suffer from depression or behavior problems may be more likely to play potentially fatal "choking games" to achieve a euphoric high than young people who don't have mental health issues, a French study suggests.

Valbenazine significantly reduced involuntary movements associated with tardive dyskinesia in patients with primary mood disorders, at both 6 weeks and 48 weeks after beginning the treatment, according to a published analysis.



BLOG: On January 18, 2018, in Sacramento California, new mother Jessica Porten went to see a women’s health nurse practitioner. She was 4 months postpartum and had not been seen by her obstetric provider since giving birth.

BLOG: Recent qualitative studies on subjects treated with psilocybin may begin to help us understand the subjective experience caused by the drug that may lead to its antidepressant effects.

BLOG: We psychiatrists read so much about physicians being “difficult patients.” What about when the shoe is on the other foot?



Rikinkumar Patel, MD, MPH; Mandeep Kaur, MD; Ahmed Elmaadawi, MD; Zeeshan Mansuri, MD, MPH; Kaushal Shah, MBBS, MPH; Suhayl Nasr, MD
Joseph Goldberg, MD; Cynthia Siu, PhD; Yongcai Mao, PhD; Joyce Tsai, PhD; Andrei Pikalov, MD, PhD; Joseph Calabrese, MD; Antony Loebel, MD
Karen Anderson, MD; Mat Davis, PhD; Stewart Factor, DO; Robert Hauser, MD, MBA; Lars Jarskog, MD; Joohi Jimenez-Shahed, MD; Rajeev Kumar, MD, FRCPC; Stanislaw Ochudlo, MD, PhD; William Ondo, MD; Hubert Fernandez, MD
Stanley Caroff, MD; Fan Mu, PhD; Rajeev Ayyagari, PhD; Traci Schilling, MD; Victor Abler, DO; Benjamin Carroll, PharmD



J. John Mann, MD and Charles Raison, MD discuss whether suicide is a result of genetics or an individual’s environment.

J. John Mann, MD, of Columbia University, and Charles Raison, MD, Psych Congress Steering Committee member, discuss which questions clinicians should ask to best evaluate suicide risk.

Marlene Freeman, MD, discusses her poster presented at Psych Congress 2018, "EnBrace HR for Depression Treatment and Prevention in Women Trying to Conceive and Early Pregnancy." Poster and video sponsored by JayMac Pharmaceuticals, LLC.



Listen as Psych Congress Steering Committee member Charles Raison, MD, discusses a book he coauthored, The New Mind-Body Science of Depression, with David Van Nuys, PhD, on Shrink Rap Radio.